565740
α-淀粉样蛋白前体蛋白质调节剂
≥95% (HPLC), solid, PKC activator, Calbiochem®
别名:
α-淀粉样蛋白前体蛋白质调节剂
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C27H30F3N3O3
化学文摘社编号:
分子量:
501.54
MDL number:
UNSPSC Code:
12352202
NACRES:
NA.77
Assay:
≥95% (HPLC)
Form:
solid
Quality level:
Storage condition:
OK to freeze, protect from light
产品名称
α-淀粉样蛋白前体蛋白质调节剂, A cell-permeable benzolactam derived PKC activator (Ki = 11.9 nM for PKCα) that efficiently enhances non-amyloidogenic α-processing of amyloid precursor protein (APP) even at 100 nM in human fibroblast AG06848.
Quality Level
assay
≥95% (HPLC)
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, protect from light
color
orange
solubility
methanol: 1 mg/mL, DMSO: 50 mg/mL
shipped in
wet ice
storage temp.
−20°C
SMILES string
FC(F)(F)c1ccc(cc1)\C=C\C=C\C(=O)Nc2cc3c(cc2)N([C@H](C(=O)N[C@@H](C3)CO)C(C)C)C
InChI
1S/C27H30F3N3O3/c1-17(2)25-26(36)32-22(16-34)15-19-14-21(12-13-23(19)33(25)3)31-24(35)7-5-4-6-18-8-10-20(11-9-18)27(28,29)30/h4-14,17,22,25,34H,15-16H2,1-3H3,(H,31,35)(H,32,36)/b6-4+,7-5+/t22-,25-/m0/s1
InChI key
WOLVEMPZUIFSII-IHHOKICGSA-N
General description
一种细胞渗透性PKC激活剂（PKCα的Ki=11.9 nM），有效增强淀粉样前体蛋白（APP）的非淀粉样α加工，但缺乏任何促肿瘤活性。
一种细胞渗透性苯并内酰胺衍生的PKC激活剂（PKCα的Ki=11.9 nM），即使在100 nM时，也可有效增强人成纤维细胞AG06848中淀粉样前体蛋白（APP）的非淀粉样α-加工。显示肿瘤促进活性显着丧失。
Biochem/physiol Actions
主要靶标
PKC
PKC
产物不与ATP竞争。
可逆：否
细胞可渗透性：是
靶标Ki：对于活化PKC为11.9 nMα
Packaging
用惰性气体包装
Preparation Note
复溶后，等分并冷冻保存（-20°C）。贮备溶液在-20°C下可稳定保存至多6个月。
Other Notes
Kozikowski, A.P., et al. 2003.J. Med. Chem.46, 364.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
毒性：标准处理（A）
存储类别
11 - Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Ana-Maria Cujba et al.
Cell reports, 38(9), 110425-110425 (2022-03-03)
The HNF1αp291fsinsC truncation is the most common mutation associated with maturity-onset diabetes of the young 3 (MODY3). Although shown to impair HNF1α signaling, the mechanism by which HNF1αp291fsinsC causes MODY3 is not fully understood. Here we use MODY3 patient and
Sisi Feng et al.
Cell reports, 33(10), 108455-108455 (2020-12-10)
The ever-increasing therapeutic and pharmaceutical demand for liver cells calls for systems that enable mass production of hepatic cells. Here we describe a large-scale suspension system that uses human endoderm stem cells (hEnSCs) as precursors to generate functional and transplantable
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| 565740-1MG | 04055977267648 |